Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A new Scientific Statement issued by The Endocrine Society represents a comprehensive evaluation of available information on the prevalence and medical consequences of the use of performance-enhancing drugs (PEDs). The statement highlights the clinical pharmacology, adverse effects and detection of many substances often classified as PEDs, identifies gaps in knowledge and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem.
PEDs are synonymous with the names of certain elite athletes who have been accused of using illegal substances to gain a competitive edge, but in reality professional athletes make up only a small fraction of the nation's 3 million PED users. Most users are non-athlete weightlifters who are more focused on personal appearance, in that they want to look leaner and more muscular. But according to the Society's new statement, PED use can take a heavy and dangerous toll on personal health.
"There is a widespread misperception that PED use is safe or that adverse effects are manageable," said Shalender Bhasin, MD, Director, Research Program in Men's Health: Aging and Metabolism, at the Brigham and Women's Hospital, and chair of the task force that developed the statement. "The truth is, PED use has been linked to increased risk of death and a wide variety of cardiovascular, psychiatric, metabolic, renal and musculoskeletal disorders."
There are several categories of PEDs, but the most frequently used substances are lean mass builders which are generally anabolic drugs that increase muscle mass and/ or reduce fat mass. By far the most prevalent illicit PEDs are anabolic-androgenic steroids (AAS), followed by human growth hormone, insulin-like growth factor-1 (IGF-1), insulin, stimulants, erythropoietin, diuretics and even thyroid hormone.
PED users at greatest risk for adverse effects are those who develop a dependence on the drugs and accumulate many years of exposure. According to the statement, nearly a third of AAS users will develop AAS dependence and about 1 million men have experienced AAS dependence at some time.
PED use can result in infertility, gynecomastia, sexual dysfunction, hair loss, acne and testicular atrophy. Furthermore, athletes and non-athlete weightlifters that use PEDs often engage in other high-risk health behaviors including concomitant use of other drugs such as alcohol and opiates with AAS. AAS users may be more susceptible to rage, antisocial and violent behaviors, and suicide.
"The use of performance-enhancing drugs is far more prevalent than is generally believed and deserves substantially greater investigation of its medical consequences, mechanisms, prevention and treatment," said Harrison G. Pope, Jr. of McClean Hospital at the Harvard Medical School in Belmont, MA, and another author of the statement. "Long-term observational studies (registries) to determine the health risks associated with PED use are a public health imperative."
Much of the national effort has focused on measures to detect, punish and shame elite athletes in the hope that these measures would discourage PED use by the rank-and-file PED user, who is not an athlete. The empiric experience of the past 20 years suggests that this approach has had very limited success. The statement emphasizes that PED use by athletes and non-athlete weightlifters are two distinct cultural phenomena; these two categories of PED users differ in their motivation to use PEDs and in their sociodemographic profile. The Position Statement makes the point that the PED use by non-athlete weightlifters is a major public health problem associated with potentially serious adverse health consequences.
The statement highlights several obstacles to better appreciating the adverse effects of PEDs. These include:
Other authors of the statement include: Ruth Wood of the University of Southern California; Alan Rogol of the University of Virginia; Fred Nyberg of Karolinska Institute in Stockholm, Sweden; Jag Khalsa of the National Institute of Drug Abuse in Bethesda, MD; and Larry Bowers of the United States Anti-Doping Agency in Colorado Springs, CO.
The statement, "The Adverse Health Consequences of the Use of Performance-Enhancing Drugs" was published online in Endocrine Reviews, a journal of The Endocrine Society.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Sports Medicine / Fitness category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Society, The Endocrine. "The health consequences of performance-enhancing drugs." Medical News Today. MediLexicon, Intl., 23 Dec. 2013. Web.
18 Apr. 2014. <http://www.medicalnewstoday.com/releases/270366>
Society, T. (2013, December 23). "The health consequences of performance-enhancing drugs." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/270366.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.